Login / Signup

Registration-directed phase 1/2 trial of irinotecan for pediatric solid tumors.

Atsushi MakimotoHideo MugishimaTakashi TagaYuji IshidaYoshihisa NagatoshiKohmei IdaMasaaki KumagaiToshimi KimuraYasuo OhashiMichio Kaneko
Published in: Pediatrics international : official journal of the Japan Pediatric Society (2019)
The RD of IRI in this treatment schedule was 40 mg/m2 /day. IRI did not cause tumor shrinkage but might help to stabilize refractory pediatric solid tumors. Based on the accumulating evidence from international studies of the efficacy of IRI against refractory pediatric solid tumors, the Japanese regulatory authority approved its use for this indication in 2011.
Keyphrases
  • combination therapy
  • smoking cessation